Treatment with thalidomide and cyclophosphamide (TCID) is superior to vincristine (VID) and to vinorelbine (VRID) regimens in patients with refractory or recurrent multiple myeloma
Treatment of relapsed or refractory multiple myeloma remains a challenge and novel treatment regimen are required. Here, a matched pair analysis was performed comparing TCID (thalidomide, cyclophosphamide, idarubicin, dexamethasone) treatment to the treatment of patients with VID (vincristine, idaru...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2012
|
| In: |
Indian journal of hematology and blood transfusion
Year: 2011, Jahrgang: 28, Heft: 2, Pages: 67-76 |
| ISSN: | 0974-0449 |
| DOI: | 10.1007/s12288-011-0103-1 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1007/s12288-011-0103-1
|
| Verfasserangaben: | Britta Auel, Hartmut Goldschmidt, Thomas Geer, Thomas M. Moehler, Uwe Platzbecker, Ralph Naumann, Igor Blau, Mathias Hänel, Wolfgang Knauf, Holger Nückel, Hans-Jürgen Salwender, Christof Scheid, Katja Weisel, Marcus Gorschlüter, Axel Glasmacher, Ingo G.H. Schmidt-Wolf, The German Refractory Myeloma Study Group |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1580292283 | ||
| 003 | DE-627 | ||
| 005 | 20220814230301.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180822r20122011xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12288-011-0103-1 |2 doi | |
| 035 | |a (DE-627)1580292283 | ||
| 035 | |a (DE-576)510292283 | ||
| 035 | |a (DE-599)BSZ510292283 | ||
| 035 | |a (OCoLC)1341017471 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Auel, Britta |e VerfasserIn |0 (DE-588)1165182823 |0 (DE-627)1029343284 |0 (DE-576)510293298 |4 aut | |
| 245 | 1 | 0 | |a Treatment with thalidomide and cyclophosphamide (TCID) is superior to vincristine (VID) and to vinorelbine (VRID) regimens in patients with refractory or recurrent multiple myeloma |c Britta Auel, Hartmut Goldschmidt, Thomas Geer, Thomas M. Moehler, Uwe Platzbecker, Ralph Naumann, Igor Blau, Mathias Hänel, Wolfgang Knauf, Holger Nückel, Hans-Jürgen Salwender, Christof Scheid, Katja Weisel, Marcus Gorschlüter, Axel Glasmacher, Ingo G.H. Schmidt-Wolf, The German Refractory Myeloma Study Group |
| 264 | 1 | |c 2012 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online: 18 August 2011 | ||
| 500 | |a Gesehen am 22.08.2018 | ||
| 520 | |a Treatment of relapsed or refractory multiple myeloma remains a challenge and novel treatment regimen are required. Here, a matched pair analysis was performed comparing TCID (thalidomide, cyclophosphamide, idarubicin, dexamethasone) treatment to the treatment of patients with VID (vincristine, idarubicin, dexamethasone) or with VRID (vinorelbine, idarubicin, dexamethasone) for relapsed or refractory multiple myeloma. In total, 197 patients were enrolled in multicenter trials. After matching for important prognostic variables 46 matched-pairs (total of 138 patients) could be analysed with regard to survival, toxicity and efficacy. Interestingly, a significant improvement of overall response rate (ORR) for TCID treatment compared to VID and VRID was found. In addition, TCID treatment also led to a significantly higher overall survival (OS) as well as progression-free survival (PFS) compared to VID and VRID. In conclusion, TCID treatment appears to be superior to VRID and VID treatment in patients with progressive or refractory myeloma. | ||
| 534 | |c 2011 | ||
| 650 | 4 | |a Blood Transfusion Medicine | |
| 650 | 4 | |a Dexamethasone | |
| 650 | 4 | |a Hematology | |
| 650 | 4 | |a Human Genetics | |
| 650 | 4 | |a Idarubicin | |
| 650 | 4 | |a Medicine & Public Health | |
| 650 | 4 | |a Myeloma | |
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Thalidomide | |
| 650 | 4 | |a Vinorelbine | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 700 | 1 | |a Möhler, Thomas |e VerfasserIn |0 (DE-588)1014877261 |0 (DE-627)705298051 |0 (DE-576)34979572X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Indian journal of hematology and blood transfusion |d Neu Delhi : Springer India, 2007 |g 28(2012), 2, Seite 67-76 |h Online-Ressource |w (DE-627)564751227 |w (DE-600)2422370-0 |w (DE-576)306836130 |x 0974-0449 |7 nnas |a Treatment with thalidomide and cyclophosphamide (TCID) is superior to vincristine (VID) and to vinorelbine (VRID) regimens in patients with refractory or recurrent multiple myeloma |
| 773 | 1 | 8 | |g volume:28 |g year:2012 |g number:2 |g pages:67-76 |g extent:10 |a Treatment with thalidomide and cyclophosphamide (TCID) is superior to vincristine (VID) and to vinorelbine (VRID) regimens in patients with refractory or recurrent multiple myeloma |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12288-011-0103-1 |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180822 | ||
| 993 | |a Article | ||
| 994 | |a 2012 | ||
| 998 | |g 1014877261 |a Möhler, Thomas |m 1014877261:Möhler, Thomas |d 50000 |e 50000PM1014877261 |k 0/50000/ |p 4 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |e 910000PG102258023X |e 910100PG102258023X |k 0/910000/ |k 1/910000/910100/ |p 2 | ||
| 999 | |a KXP-PPN1580292283 |e 3022953879 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"person":[{"display":"Auel, Britta","family":"Auel","role":"aut","given":"Britta"},{"display":"Goldschmidt, Hartmut","family":"Goldschmidt","given":"Hartmut","role":"aut"},{"given":"Thomas","role":"aut","display":"Möhler, Thomas","family":"Möhler"}],"id":{"eki":["1580292283"],"doi":["10.1007/s12288-011-0103-1"]},"name":{"displayForm":["Britta Auel, Hartmut Goldschmidt, Thomas Geer, Thomas M. Moehler, Uwe Platzbecker, Ralph Naumann, Igor Blau, Mathias Hänel, Wolfgang Knauf, Holger Nückel, Hans-Jürgen Salwender, Christof Scheid, Katja Weisel, Marcus Gorschlüter, Axel Glasmacher, Ingo G.H. Schmidt-Wolf, The German Refractory Myeloma Study Group"]},"physDesc":[{"extent":"10 S."}],"recId":"1580292283","relHost":[{"origin":[{"publisherPlace":"Neu Delhi","dateIssuedDisp":"2007-","publisher":"Springer India","dateIssuedKey":"2007"}],"pubHistory":["Nachgewiesen 23.2007 -"],"note":["Gesehen am 10.12.13"],"title":[{"title":"Indian journal of hematology and blood transfusion","title_sort":"Indian journal of hematology and blood transfusion"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Treatment with thalidomide and cyclophosphamide (TCID) is superior to vincristine (VID) and to vinorelbine (VRID) regimens in patients with refractory or recurrent multiple myelomaIndian journal of hematology and blood transfusion","recId":"564751227","name":{"displayForm":["Indian Society of Hematology & Transfusion Medecine"]},"physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["564751227"],"issn":["0974-0449"],"zdb":["2422370-0"]},"language":["eng"],"part":{"pages":"67-76","year":"2012","text":"28(2012), 2, Seite 67-76","issue":"2","volume":"28","extent":"10"}}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Published online: 18 August 2011","Gesehen am 22.08.2018"],"origin":[{"dateIssuedDisp":"2012","dateIssuedKey":"2012"}],"title":[{"title":"Treatment with thalidomide and cyclophosphamide (TCID) is superior to vincristine (VID) and to vinorelbine (VRID) regimens in patients with refractory or recurrent multiple myeloma","title_sort":"Treatment with thalidomide and cyclophosphamide (TCID) is superior to vincristine (VID) and to vinorelbine (VRID) regimens in patients with refractory or recurrent multiple myeloma"}]} | ||
| SRT | |a AUELBRITTATREATMENTW2012 | ||